Table 1.
Clinical characteristics
| Variables | Total (n = 67) | CE (n = 42) | LAA (n = 25) | Statistic | P |
|---|---|---|---|---|---|
| Age, Median (Q1, Q3) | 68 (59, 75) | 72.5 (59.5, 77) | 68 (60, 73) | 601 | 0.327 |
| Gender, n (%) | 0.658 | 0.417 | |||
| Female | 27 (40) | 19 (45) | 8 (32) | ||
| Male | 40 (60) | 23 (55) | 17 (68) | ||
| Systolic blood pressure, Mean ± SD | 152.04 ± 24.8 | 152.76 ± 23.52 | 150.84 ± 27.28 | 0.293 | 0.771 |
| Diastolic blood pressure, Mean ± SD | 85.4 ± 14.3 | 86.07 ± 12.52 | 84.28 ± 17.11 | 0.456 | 0.651 |
| Glucose, Median (Q1, Q3) | 6.7 (6.27, 8.09) | 6.68 (6.18, 7.79) | 6.85 (6.5, 8.25) | 450 | 0.334 |
| NHISS, Mean ± SD | 15.22 ± 7.02 | 15.45 ± 7.37 | 14.84 ± 6.53 | 0.354 | 0.725 |
| Hypertension, n (%) | 41 (61) | 22 (52) | 19 (76) | 2.754 | 0.097 |
| Diabetes mellitus, n (%) | 10 (15) | 4 (10) | 6 (24) | Fisher | 0.157 |
| Smoking, n (%) | 19 (28) | 8 (19) | 11 (44) | 3.653 | 0.056 |
| Treatment, n (%) | 0.008 | 0.929 | |||
| no-rtPA | 42 (63) | 27 (64) | 15 (60) | ||
| rtPA | 25 (37) | 15 (36) | 10 (40) | ||
| 90 day-mRS, n (%) | 1.519 | 0.218 | |||
| 0–2 | 22 (33) | 11 (26) | 11 (44) | ||
| 3–6 | 45 (67) | 31 (74) | 14 (56) | ||
| Sema7A, Median (Q1, Q3) | 2 (1.12, 3.38) | 2.5 (1.56, 3.94) | 1 (0.25, 1.25) | 831.5 | < 0.001 |
| rSema7A, Median (Q1, Q3) | 0.06 (0.04, 0.11) | 0.09 (0.06, 0.12) | 0.03 (0.01, 0.07) | 798 | < 0.001 |
| CD163, Median (Q1, Q3) | 0.25 (0, 1.38) | 0.62 (0, 1.44) | 0 (0, 0.5) | 616.5 | 0.218 |
| rCD163, Median (Q1, Q3) | 0.01 (0, 0.08) | 0.02 (0, 0.08) | 0 (0, 0.1) | 598 | 0.327 |
Abbreviation large-artery atherosclerosis (LAA), cardioembolism (CE), the National Institutes of Health Stroke Scale (NIHSS), recombinant tissue plasminogen activator (rt-PA, the modified Rankin score (mRS) and semaphorin-7A (Sema7A). The macrophage ratios (the number of positive macrophages divide the number of all macrophages) regarding Sema7A and CD163 were abbreviated as rSema7A and rCD163